Clinical Pharmacology of Antibacterial Agents

Infectious Diseases of the Fetus and Newborn Infant

Volumn , Issue , 2006, Pages 1223-1267

  Sáez Llorens, Xavier ^a,b   McCracken, George H ^c  

^a UNIVERSIDAD DE PANAMÁ   (Panama)

^b Hospital del Niiio   (Panama)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649833471     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-72-160537-0/50039-6     Document Type: Chapter

References (513)

1. Roberts RJ Drug Therapy in Infants: Pharmacologic Principles and Clinical Experience 1984, 3. WB Saunders, Philadelphia.
2. Huang NN, High RH Comparision of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953, 42:657.
3. Weiss CF, Glazko AJ, Weston JK Chloramphenicol in the newborn infant: a physiologic explanation of its toxicity when given in doses. N Engl J Med 1960, 262:787.
4. Kauffman RE, Thirumoorthi MC, Buckley JA, et al. Relative bioavailability of intravenous chloramphenicol succinate and oral chloramphenicol palmitate in infants and children. J Pediatr 1981, 99:963.
5. Shankaran S, Kauffman RE Use of chloramphenicol palmitate in neonates. J Pediatr 1984, 105:113.
6. Boccazzi A, Rizzo M, Caccamo ML, et al. Comparison of the concentrations of ceftazidime in the serum of newborn infants after intravenous and intramuscular administration. Antimicrob Agents Chemother 1983, 24:955.
7. Mulhall A Antibiotic treatment of neonates-does route of administration matter?. Dev Pharmacol Ther 1985, 8:1.
8. Ristuccia AM Chloramphenicol: clinical pharmacology in pediatrics. Ther Drug Monit 1985, 7:159.
9. Beutler E Drug-induced hemolytic anemia. Pharmacol Rev 1969, 21:73.
10. Friis-Hansen B Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 1961, 28:169.
11. McCracken GH Clinical pharmacology of gentamicin in infants 2 to 24 months of age. Am J Dis Child 1972, 124:884.
12. Wise R The clinical relevances of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacol 1977, 11:463.
13. Kurz H, Mauser-Ganshorn A, Stickel HH Differences in the binding of drugs to plasma proteins from newborn and adult man: I. Eur J Clin Pharmacol 1977, 11:463.
14. Schaad UB, Hayton WL, Stoeckel K Single-dose certriaxone kinetics in the newborn. Clin Pharmacol Ther 1985, 37:522.
15. Silverman WA, Andersen DH, Blanc WA, et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956, 18:614.
16. Brodersen R, Friis-Hansen B, Stern L Drug-induced displacement of bilirubin from albumin in the newborn. Dev Pharmacol Ther 1983, 6:217.
17. Cashore WJ, Oh W, Brodersen R Bilirubin-displacing effect of furosemide and sulfisoxazole: an in vitro and in vivo study in neonatal serum. Dev Pharmacol Ther 1983, 6:230.
18. Stutman HR, Parker KM, Marks MI Potential of moxalactam and other new antimicrobial agents for bilirubin-albumin displacement in neonates. Pediatrics 1985, 75:294.
19. Gulian JM, Gonard V, Dalmasso C, et al. Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of "free" bilirubin and erythrocyte-bound bilirubin. J Antimicrob Chemother 1987, 19:823.
20. Brodersen R, Ebbesen F Bilirubin-displacing effect of ampicillin, indomethacin, chlorpromazine, gentamicin, and parabens in vitro and in newborn infants. J Pharm Sci 1983, 72:248.
21. Sakamoto H, Murakawa T, Hirose T, et al. Effect of ceftizoxime, a new cephalosporin antibiotic, on binding of bilirubin to human serum albumin. Chemotherapy 1983, 29:244.
22. Walker PC Neonatal bilirubin toxicity: a review of kernicterus and the implications of drug-induced bilirubin displacement. Clin Pharmacokinet 1987, 13:26.
23. Robertson A, Fink S, Karp W Effect of cephalosporins on bilirubin-albumin binding. J Pediatr 1988, 112:291.
24. Guignard JP Drugs and the neonatal kidney. Dev Pharmacol Ther 1982, 4(Suppl 1):19.
25. Myers MG, Roberts RJ, Mirhij NJ Effects of gestational age, birth weight, and hypoxemia on pharmacokinetics of amikacin in serum in infants. Antimicrob Agents Chemother 1977, 11:1027.
26. Handwerger S, Tomasz A Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis 1985, 7:368.
27. Moellering RC Rationale for use of antimicrobial combinations. Am J Med 1983, 75(Suppl 2A):4.
28. Giamarellou H Aminoglycosides plus beta-lactams against gram negative organisms: evaluation of in vitro synergy and chemical interactions. Am J Med 1982, 80(SUPPL. 6B):126.
29. Holm SE Interactions between β-lactam and other antibiotics. Rev Infect Dis 1986, 8:S305.
30. Schauf V, Deveikis A, Riff L, et al. Antibiotic-killing kinetics of group B streptococci. J Pediatr 1976, 89:194.
31. Cooper MD, Keeney RE, Lyons SF, et al. Synergistic effects of ampicillin-aminoglycoside combinations on group B streptococci. Antimicrob Agents Chemother 1979, 15:484.
32. Scheld WM, Alliegro GM, Field MR, et al. Synergy between ampicillin and gentamicin in experimental meningitis due to group B streptococci. J Infect Dis 1982, 146:100.
33. Calderwood SA, Wennersten CBG, Moellering RC, et al. Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother 1977, 12:401.
34. Scheld WM, Fletcher DD, Fink FN, et al. Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes. J Infect Dis 1979, 140:287.
35. Kaplan JM, McCracken GH, Horton LJ, et al. Pharmacologic studies in neonates given large dosages of ampicillin. J Pediatr 1974, 84:571.
36. Watanakunakorn C, Glotzbecker C Enhancement of the effects of antistaphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother 1974, 6:802.
37. McCracken GH, Nelson JD, Thomas ML Discrepancy between carbenicillin and ampicillin activities against enterococci and Listeria. Antimicrob Agents Chemother 1973, 3:343.
38. Levy RH, Bauer LA Basic pharmacokinetics. Ther Drug Monit 1986, 8:47.
39. Schentag JJ, Jusko WJ, Plaut ME, et al. Tissue persistence of gentamicin in man. JAMA 1977, 238:327.
40. Siegel JD, McCracken GH, Nelson JD Pharmacokinetic properties of netilmicin in newborn infants. Antimicrob Agents Chemother 1979, 15:246.
41. Schaad UB, McCracken GH, Nelson JD Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980, 96:119.
42. Haughey DB, Hilligoss DM, Grassi A, et al. Two-compartment gentamicin pharmacokinetics in premature neonates: a comparison to adults with decreased glomerular filtration rates. J Pediatr 1980, 96:325.
43. Schaad UB, McCracken GH, Loock CA, et al. Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis. Antimicrob Agents Chemother 1980, 17:406.
44. Odio C, Thomas ML, McCracken GH Pharmacokinetics and bacteriological efficacy of mezlocillin in experimental Escherichia coli and Listeria monocytogenes meningitis. Antimicrob Agents Chemother 1984, 25:427.
45. McCracken GH, Sakata Y, Olsen KD Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1. Antimicrob Agents Chemother 1985, 27:655.
46. Jacobs MR, Myers C Diagnostic microbiology and therapeutic drug monitoring in pediatric infectious diseases. Pediatr Clin North Am 1983, 30:135.
47. Doering PL, Stewart RB The extent and character of drug consumption during pregnancy. JAMA 1978, 239:843.
48. Brocklebank JC, Ray WA, Federspiel CF, et al. Drug prescribing during pregnancy: a controlled study of Tennessee Medicaid recipients. Am J Obstet Gynecol 1978, 132:235.
49. Philipson A The use of antibiotics in pregnancy. J Antimicrob Chemother 1983, 12:101.
50. Tropper PJ, Petrie RH Placental exchange. The Human Placenta: Clinical Perspectives 1987, 199. Aspen Publishers, Rockville, Md. J.P. Lavery (Ed.).
51. Juchau MR, Dyer DC Pharmacology of the placenta. Pediatr Clin North Am 1972, 19:65.
52. Philipson A, Sabath LD, Charles D Transplacental passage of erythromycin and clindamycin. N Engl J Med 1973, 288:1219.
53. Bernard B, Abate M, Thielen PF, et al. Maternal-fetal pharmacological activity of amikacin. J Infect Dis 1977, 135:925.
54. Bernard B, Garcia-Cazares SJ, Ballard CA, et al. Tobramycin: maternal-fetal pharmacology. Antimicrob Agents Chemother 1977, 11:688.
55. Matsuda S, Mori S, Tanno M, et al. Evaluation of amikacin in obstetric and gynecological field. Jpn J Antibiot 1974, 27:633.
56. Buckingham M, Welply G, Miller JF, et al. Gastrointestinal absorption and transplacental transfer of amoxicillin during labour and the influence of metoclopramide. Curr Med Res Opin 1975, 3:392.
57. Nau H Clinical pharmacokinetics in pregnancy andperinatology: II. Penicillins. Dev Pharmacol Ther 1987, 10:174.
58. Kafetzis DA, Brater DC, Fanourgakis JE Materno-fetal transfer of azlocillin. J Antimicrob Chemother 1983, 12:157.
59. Charles D, Larsen B Placental transfer of antibiotics. Antimicrobial Therapy 1984, 519. Raven Press, New York. A.M. Ristuccia, B.A. Cunha (Eds.).
60. Bernard B, Barton L, Abate M, et al. Maternal-fetal transfer of cefazolin in the first twenty weeks trimester of pregnancy. J Infect Dis 1977, 136:377.
61. Dekel A, Elian I, Gibor Y, et al. Transplacental passage of cefazolin in the first trimester of pregnancy. Eur J Obstet Gynecol Reprod Biol 1980, 10:303.
62. Cho N, Ito T, Saito T, et al. Clinical studies on cefazolin in the field of obstetrics and gynecology. Chemotherapy 1970, 18:770.
63. Shimizu K Cefoperazone: absorption, excretion, distribution, and metabolism. Clin Ther 1980, 3(Spec. Issue):60.
64. Briggs GG, Freeman RK, Yaffe SJ Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk 1986, Williams & Wilkins, Baltimore. 2nd ed.
65. Kafetzis DA, Lazarides CV, Siafas CA, et al. Transfer of cefotaxime in human milk and from mother to foetus. J Antimicrob Chemother 1980, 6(SUPPL. A):135.
66. Matsuda S, Tanno M, Kashiwakura T, et al. Laboratory and clinical studies on cefotaxin in the field of obstetric and gynecology. Chemotherapy (Tokyo) 1978, 26(Suppl 1):460.
67. Nankun C, Uerhara K, Sugizaki K, et al. Clinical studies of cefoxitin in the field of obstetrics and gynecology. Chemotherapy (Tokyo) 1978, 26(Suppl 1):468.
68. Bergongne-Berezin E, Morel C, Kafe H, et al. Étude pharmacocinétique chez l'homme de la cefoxitime: diffusion intrabronchique et transplacentaire. Therapie 1979, 34:345.
69. Motomura R, Kohno M, Mori H, et al. Basic and clinical studies of ceftizoxime in obstetrics and gynecology. Chemotherapy (Tokyo) 1980, 28(Suppl 5):888.
70. Kafetzis DA, Brater DC, Fanourgakis JE, et al. Ceftriaxone distribution between maternal blood and fetal blood and tissues at parturition and between blood and milk post partum. Antimicrob Agents Chemother 1983, 23:870.
71. Craft I, Mullinger BM, Kennedy MRK Placental transfer of cefuroxime. Br J Obstet Gynaecol 1981, 88:141.
72. Bousfield P, Browning AK, Mullinger BM, et al. Cefuroxime: potential use in pregnant women at term. Br J Obstet Gynaecol 1981, 88:146.
73. Coppi G, Berti MA, Chehade A, et al. A study of the transplacental transfer of cefuroxime in humans. Curr Ther Res 1982, 32:712.
74. Creatsas G, Pavlatos M, Lolis D, et al. A study of the kinetics of cephapirin and cephalexin in pregnancy. Curr Med Res Opin 1980, 7:43.
75. Morrow S, Palmisano P, Cassady G The placental transfer of cephalothin. J Pediatr 1968, 73:262.
76. Scott WC, Warner RF Placental transfer of chloramphenicol (Chloromycetin). JAMA 1950, 142:1331.
77. Ross S, Burke FG, Sites J, et al. Placental transmission of chloramphenicol (Chloromycetin). JAMA 1950, 142:1361.
78. Burns LE, Hodgman JE, Cass AB Fatal circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med 1959, 261:1318.
79. Weinstein AJ, Gibbs RS, Gallagher M Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol 1976, 124:688.
80. Herngren L, Ehrnebo M, Boreus LO Drug binding to plasma proteins during human pregnancy and in the perinatal period: studies on cloxacillin and alprenolol. Dev Pharmacol Ther 1983, 6:110.
81. MacAulay MA, Charles D Placental transmission of colistimethate. Clin Pharmacol Ther 1967, 8:578.
82. MacAylay MA, Berg SR, Charles D Placental transfer of dicloxacillin at term. Am J Obstet Gynecol 1968, 102:1162.
83. Depp R, Kind AC, Kirby WMM, et al. Transplacental passage of methicillin and dicloxacillin into the fetus and amniotic fluid. Am J Obstet Gynecol 1970, 107:1054.
84. Kiefer L, Rubin A, McCoy JB, et al. The placental transfer of erythromycin. Am J Obstet Gynecol 1955, 69:174.
85. Yoshioka H, Monma T, Matsuda S Placental transfer of gentamicin. J Pediatr 1972, 80:121.
86. L'Hommedieu CS, Nicholas D, Armes DA, et al. Potentiation of magnesium sulfate-induced neuromuscular weakness by gentamicin, tobramycin, and amikacin. J Pediatr 1983, 102:629.
87. Heikkila A, Renkonen OV, Erkkola R Pharmacokinetics and transplacental passage of imipenem during pregnancy. Antimicrob Agents Chemother 1992, 36:2652.
88. Good RG, Johnson GH The placental transfer of kanamycin during late pregnancy. Obstet Gynecol 1971, 38:60.
89. Jones HC Intrauterine ototoxicity: a case report and review of literature. J Natl Med Assoc 1973, 65:201.
90. Duignan NM, Andrews J, Williams JD Pharmacological studies with lincomycin in late pregnancy. BMJ (Clin Res) 1975, 3:75.
91. Mickal A, Panzer JD The safety of lincomycin in pregnancy. Am J Obstet Gynecol 1975, 121:1071.
92. MacAulay MA, Molloy WB, Charles D Placental transfer of methicillin. Am J Obstet Gynecol 1973, 115:58.
93. Perry JE, LeBlanc AL Transfer of nitrofurantoin across the human placenta. Tex Rep Biol Med 1967, 25:265.
94. Wasz-Höckert O, Nummi S, Vuopala S, et al. Transplacental passage of azidocillin, ampicillin and penicillin G during early and late pregnancy. Scand J Infect Dis 1970, 2:125.
95. Greene HJ, Hobby GL Transmission of penicillin through human placenta. Proc Soc Exp Biol Med 1944, 57:282.
96. Woltz JHE, Zintel HA The transmission of penicillin to amniotic fluid and fetal blood in the human. Am J Obstet Gynecol 1945, 50:330.
97. Woltz JHE, Wiley MM Transmission of streptomycin from maternal blood to the fetal circulation and the amniotic fluid. Proc Soc Exp Biol Med 1945, 60:106.
98. Conway N, Birt BD Streptomycin in pregnancy: effect on the foetal ear. BMJ 1965, 2:260.
99. Donald PR, Sellars SL Streptomycin ototoxicity in the unborn child. S Afr Med J 1981, 60:316.
100. Speert H Placental transmission of sulfathiazole and sulfadiazine and its significance for fetal chemotherapy. Am J Obstet Gynecol 1943, 45:200.
101. Ziai M, Finland M Placental transfer of sulfamethoxypyridazine. N Engl J Med 1957, 257:1180.
102. Sparr RA, Pritchard JA Maternal and newborn distribution and excretion of sulfamethoxypyridazine (Kynex). Obstet Gynecol 1958, 12:131.
103. Kantor HI, Sutherland DA, Leonard JT, et al. Effect on bilirubin metabolism in the newborn of sulfisoxazole administered to the mother. Obstet Gynecol 1961, 17:494.
104. Brown AK, Cevik N Hemolysis and jaundice in the newborn following maternal treatment with sulfamethoxypyridazine (Kynex). Pediatrics 1965, 36:742.
105. Perkins RP Hydrops fetalis and stillbirth in a male glucose-6-phosphate dehydrogenase-deficient fetus possibly due to maternal ingestion of sulfisoxazole: a case report. Am J Obstet Gynecol 1971, 111:379.
106. Azad Khan AK, Truelove SC Placental and mammary transfer of sulphasalazine. BMJ 1979, 2:1553.
107. Esbjörner E, Järnerot G, Wranne L Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 1963, 76:137.
108. Cohlan SQ, Bevelander G, Tiamsic T Growth inhibition of prematures receiving tetracycline: a clinical and laboratory investigation of tetracycline-induced bone fluorescence. Am J Dis Child 1963, 105:453.
109. Kline AH, Blattner RJ, Lunin M Transplacental effect of tetracyclines on teeth. JAMA 1964, 188:178.
110. Kutscher AH, Zegarelli EV, Tovell HMM, et al. Discoloration of deciduous teeth induced by administration of tetracycline antepartum. Am J Obstet Gynecol 1966, 96:291.
111. LeBlanc AL, Perry JE Transfer of tetracycline across the human placenta. Tex Rep Biol Med 1967, 25:541.
112. McEwen LM Trimethoprim/sulphamethoxazole mixture in pregnancy. BMJ (Clin Res) 1971, 4:490.
113. Reid DWJ, Caillé G, Kauffman NR Maternal and transplacental kinetics of trimethoprim and sulfamethoxazole separately and in combination. Can Med Assoc J 1975, 112:67S.
114. Philipson A Pharmacokinetics of antibiotics in pregnancy and labour. Clin Pharmacokinet 1979, 4:297.
115. Mucklow JC The fate of drugs in pregnancy. Clin Obstet Gynaecol 1986, 13:161.
116. Apgar V Drugs in pregnancy. JAMA 1964, 190:840.
117. Sutherland JM, Light IJ The effect of drugs upon the developing fetus. Pediatr Clin North Am 1965, 12:781.
118. Totterman LE, Saxen L Incorporation of tetracycline into human fetal bones after maternal drug administration. Acta Obstet Gynecol Scand 1969, 48:542.
119. Lumbiganon P, Pengsaa K, Sookpranee T Ciprofloxacin in neonates and its possible adverse effect on the teeth. Pediatr Infect Dis J 1991, 10:619.
120. Krasinski K, Perkin R, Rutledge J Gray baby syndrome revisited. Clin Pediatr 1982, 21:571.
121. Boyer KM, Gottof SP Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986, 314:1665.
122. Teres FO, Matorras R, Perea AG, et al. Prevention of neonatal group B streptococcal sepsis. Pediatr Infect Dis J 1987, 6:874.
123. Yow MD, Mason EO, Leeds LJ, et al. Ampicillin prevents intrapartum transmission of group B Streptococcus. JAMA 1979, 241:1245.
124. Lewis PJ Antibiotics and breast feeding. Clin Exp Obstet Gynecol 1986, 13:124.
125. Rivera-Calimlim L The significance of drugs in breast milk: pharmacokinetic considerations. Clin Perinatol 1987, 14:51.
126. Wilson JT, Brown RD, Cherek DR, et al. Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet 1980, 5:1.
127. Kafetzis DA, Siafas CA, Georgakopoulos PA, et al. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand 1981, 70:285.
128. Fleiss PM, Richwald GA, Gordon J, et al. Aztreonam in human serum and breast milk. Br J Clin Pharmacol 1985, 19:509.
129. O'Brien TE Excretion of drugs in human milk. Am J Hosp Pharm 1974, 31:844.
130. Gerding DN, Peterson LR, Hughes CE, et al. Extravascular antimicrobial distribution in man. Antibiotics in Laboratory Medicine 1986, 960. Williams & Wilkins, Baltimore. 2nd ed. V. Lorian (Ed.).
131. Dubois M, Delapierre D, Chanteux L, et al. A study of the transplacental transfer and the mammary excretion of cefoxitin in humans. J Clin Pharmacol 1981, 21:477.
132. Dresse A, Lambotte R, Dubois M, et al. Transmammary passage of cefoxitin: additional results. J Clin Pharmacol 1983, 23:438.
133. Blanco JD, Jorgensen JH, Castaneda YS, et al. Ceftazidime levels in human breast milk. Antimicrob Agents Chemother 1983, 23:479.
134. Gerding DN, Peterson LR Comparative tissue and extravascular fluid concentrations of ceftizoxime. J Antimicrob Chemother 1982, 10(Suppl C):105.
135. Knowles JA Excretion of drugs in milk-a review. J Pediatr 1965, 66:1068.
136. Steen B, Rane A Clindamycin passage into human milk. Br J Clin Pharmacol 1982, 13:661.
137. Chyo N, Sunada H, Nohara S Clinical studies of kanamycin applied in the field of obstetrics and gynecology. Asian Med J 1962, 5:265.
138. Singlas E Tissue distribution of mezlocillin. Nouv Presse Med 1982, 11:373.
139. Varsano I, Fischl J, Shochet SB The excretion of orally ingested nitrofurantoin in human milk. J Pediatr 1973, 82:886.
140. Greene HJ, Burkhart B, Hobby GL Excretion of penicillin in human milk following parturition. Am J Obstet Gynecol 1946, 51:735.
141. Kauffman RE, O'Brien C, Gilford P Sulfisoxazole secretion into human milk. J Pediatr 1980, 97:839.
142. von Kobyletzki D, Dalhoff A, Lindemeyer H, et al. Ticarcillin serum and tissue concentrations in gynecology and obstetrics. Infection 1983, 11:144.
143. Takase Z, Shirafuji H, Uchida M, et al. Laboratory and clinical studies on tobramycin in the field of obstetrics and gynecology. Chemotherapy (Tokyo) 1975, 23:1399.
144. Wilson JT, Brown RD, Hinson JL, et al. Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio for drugs. Annu Rev Pharmacol Toxicol 1985, 25:667.
145. Catz CS, Giacoia GP Drugs and breast milk. Pediatr Clin North Am 1972, 19:151.
146. The transfer of drugs and other chemicals into human breast milk. Pediatrics 1994, 93:137. American Academy of Pediatrics, Committee on Drugs.
147. Mann CF Clindamycin and breast-feeding. Pediatrics 1980, 66:1030.
148. Neu HC Penicillins. Principles and Practice of Infectious Diseases 1985, 166. John Wiley, New York. 2nd ed. G.L. Mandell, R.G. Douglas, J.E. Bennett (Eds.).
149. Neu HC Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. Am J Med 1985, 79(Suppl 5B):2.
150. Nayler JHC Resistance to β-lactams in gram-negative bacteria: relative contributions of β-lactamase and permeability limitations. J Antimicrob Chemother 1987, 19:713.
151. Tuomanen E, Durack DT, Tomasz A Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother 1986, 30:521.
152. Siegel JD, Shannon KM, DePasse BM Recurrent infection associated with penicillin-tolerant group B streptococci: a report of two cases. J Pediatr 1981, 99:920.
153. Leggiadro RJ Penicillin- and cephalosporin-resistant Streptococcus pneumoniae: an emerging microbial threat. Pediatrics 1994, 93:500.
154. Friedland IR, McCracken GH Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994, 331:377.
155. McCracken GH, Ginsberg C, Chrane DF, et al. Clinical pharmacology of penicillin in newborn infants. J Pediatr 1973, 82:692.
156. Kaplan JM, McCracken GH Clinical pharmacology of benzathine penicillin G in neonates with regard to its recommended use in congenital syphilis. J Pediatr 1973, 82:1069.
157. Klein JO, Scharberg MJ, Buntin M, et al. Levels of penicillin in serum of newborn infants after single intramuscular doses of benzathine penicillin G. J Pediatr 1973, 82:1065.
158. Hieber JP, Nelson JD A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977, 297:410.
159. Speer ME, Taber LH, Clark DB, et al. Cerebrospinal fluid levels of benzathine penicillin G in the neonate. J Pediatr 1977, 91:996.
160. McCracken GH, Kaplan JM Penicillin treatment for congenital syphilis: a critical reappraisal. JAMA 1974, 228:855.
161. Speer ME, Mason EO, Scharnberg JT Cerebrospinal fluid concentrations of aqueous procaine penicillin G in the neonate. Pediatrics 1981, 67:387.
162. Levin B, Neill CA Oral penicillin in the newborn. Arch Dis Child 1949, 24:171.
163. McCracken GH, Nelson JD Antimicrobial Therapy for Newborns 1983, Grune & Stratton, New York. 2nd ed.
164. STD Treatment Guidelines 1985, Centers for Disease Control and Prevention, Centers for Disease Control, Atlanta.
165. McCracken GH, Mize SG, Threlkeld N Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy: report of the Second Neonatal Meningitis Cooperative Study Group. Lancet 1980, 1:787.
166. Joseph TA, Pyati SP, Jacobs N Neonatal early-onset Escherichia coli disease: the effect of intrapartum ampicillin. Arch Pediatr Adolesc Med 1998, 152:35.
167. Grossman M, Ticknor W Serum levels of ampicillin, cephalothin, cloxacillin, and nafcillin in the newborn infant. Antimicrobial Agents Chemother 1965, 5:214.
168. Axline SG, Yaffe SJ, Simon HJ Clinical pharmacology of antimicrobials in premature infants: II. Ampicillin, methicillin, oxacillin, neomycin, and colistin. Pediatrics 1967, 39:97.
169. Boe RW, Williams CPS, Bennett JV, et al. Serum levels of methicillin and ampicillin in newborn and premature infants in relation to postnatal age. Pediatrics 1967, 39:194.
170. Dahl LB, Melby K, Gutteberg TJ, et al. Serum levels of ampicillin and gentamycin in neonates of varying gestational age. Eur J Pediatr 1986, 145:218.
171. Silverio J, Poole JW Serum concentrations of ampicillin in newborn infants after oral administration. Pediatrics 1973, 51:578.
172. McCracken GH, Ginsburg CM, Clahsen JC, et al. Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability. Pediatrics 1978, 62:738.
173. Bass JW, Crowley DM, Steele RW, et al. Adverse effects of orally administered ampicillin. J Pediatr 1973, 83:106.
174. Tetzlaff TR, Ashwoth C, Nelson JD Otitis media in children less than 12 weeks of age. Pediatrics 1977, 59:827.
175. Neu HC Antistaphylococcal penicillins. Med Clin North Am 1982, 66:51.
176. Utsui Y, Yokota T Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985, 28:397.
177. Shanson DC, Johnstone D, Midgley J Control of a hospital outbreak of methicillin-resistant Staphylococcus aureus infections: value of an isolation unit. J Hosp Infect 1985, 6:285.
178. Sabath LD, Wheeler N, Laverdiere M, et al. A new type of penicillin resistance of Staphylococcus aureus. Lancet 1977, 1:443.
179. Sarff LD, McCracken GH, Thomas ML, et al. Clinical pharmacology of methicillin in neonates. J Pediatr 1977, 90:1005.
180. O'Connor WJ, Warren GH, Mandala PS, et al. Serum concentrations of nafcillin in newborn infants and children. Antimicrobial Agents Chemother 1964, 10:188.
181. Banner W, Gooch WM, Burckart G, et al. Pharmacokinetics of nafcillin in infants with low birth weights. Antimicrob Agents Chemother 1980, 17:691.
182. O'Connor WJ, Warren GH, Edrada LS, et al. Serum concentrations of sodium nafcillin in infants during the perinatal period. Antimicrobial Agents Chemother 1965, 5:220.
183. Burns LE, Hodgman JE, Wehrle PF Treatment of premature infants with oxacillin. Antimicrobial Agents Chemother 1964, 10:192.
184. Sarff LD, McCracken GH Methicillin-associated nephropathy or cystitis. J Pediatr 1977, 90:1031.
185. Kitzing W, Nelson JD, Mohs E Comparative toxicities of methicillin and nafcillin. Am J Dis Child 1981, 135:52.
186. Greene GR, Cohen E Nafcillin-induced neutropenia in children. Pediatrics 1978, 61:94.
187. Nahata MV, DeBolt SL, Powell DA Adverse effects of methicillin, nafcillin and oxacillin in pediatric patients. Dev Pharmacol Ther 1982, 4:117.
188. Mallouh AA Methicillin-induced neutropenia. Pediatr Infect Dis 1985, 4:262.
189. Neu HC Carbenicillin and ticarcillin. Med Clin North Am 1982, 66:61.
190. Nelson JD, McCracken GH Clinical pharmacology of carbenicillin and gentamicin in the neonate and comparative efficacy with ampicillin and gentamicin. Pediatrics 1973, 52:801.
191. Morehead CD, Shelton S, Kusmiesz H, et al. Pharmacokinetics of carbenicillin in neonates of normal and low birth weight. Antimicrob Agents Chemother 1972, 2:267.
192. Yoshioka H, Takimoto M, Shimizu T, et al. Pharmacokinetics of intramuscular carbenicillin in the newborn. Infection 1979, 7:27.
193. Nelson JD, Kusmiesz H, Shelton S, et al. Clinical pharmacology and efficacy of ticarcillin in infants and children. Pediatrics 1978, 61:858.
194. Nelson JD, Shelton S, Kusmiesz H Clinical pharmacology of ticarcillin in the newborn infant: relation to age, gestational age, and weight. J Pediatr 1975, 87:474.
195. Sutherland R, Beale AS, Boon RJ, et al. Antibacterial activity of ticarcillin in the presence of clavulanate potassium. Am J Med 1985, 79(Suppl 5B):13.
196. Pulverer G, Peters G, Kunstmann G In-vitro activity of ticarcillin with and without clavulanic acid against clinical isolates of gram-positive and gram-negative bacteria. J Antimicrob Chemother 1986, 17(Suppl C):1.
197. Gould IM, Wise R β-Lactamase inhibitors. The Antimicrobial Agents Annual 1 1986, 51. Elsevier, Amsterdam. P.K. Peterson, J. Verhoef (Eds.).
198. Bégué P, Quiniou F, Quinet B Efficacy and pharmacokinetics of Timentin in paediatric infections. J Antimicrob Chemother 1986, 17(Suppl):81.
199. Eliopoulos GM, Moellering RC Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med 1982, 97:755.
200. Drusano GL, Schimpff SC, Hewitt WL The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis 1984, 6:13.
201. Allan JD, Eliopoulos GM, Moellering RC The expanding spectrum of beta-lactam antibiotics. Adv Intern Med 1986, 31:119.
202. Moody JA, Peterson LR, Gerding DN In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics. Antimicrob Agents Chemother 1984, 26:256.
203. Heimann G, Föster D Pharmacokinetics of acylureidopenicillins (azlocillin, mezlocillin) in prematures and newborns. Drugs Exp Clin Res 1981, 7:287.
204. Rubio T, Wirth F, Karotkin E Pharmacokinetic studies of mezlocillin in newborn infants. J Antimicrob Chemother 1982, 9(Suppl A):241.
205. Janicke DM, Rubio TT, Wirth FH, et al. Developmental pharmacokinetics of mezlocillin in newborn infants. J Pediatr 1984, 104:773.
206. Odio C, Threlkeld N, Thomas ML, et al. Pharmacokinetics properties of mezlocillin in newborn infants. Antimicrob Agents Chemother 1984, 25:556.
207. Chiu T, Garrison RD, Fakhreddine F, et al. Mezlocillin in neonatal infections: evaluation of efficacy and toxicity. J Antimicrob Chemother 1982, 9(Suppl A):251.
208. Weingärtner L Clinical aspects of mezlocillin therapy in childhood. J Antimicrob Chemother 1982, 9(Suppl A):257.
209. Bergan T Review of the pharmacokinetics of mezlocillin. J Antimicrob Chemother 1983, 11(Suppl C):1.
210. Heimann G Pharmacokinetics and clinical aspects of azlocillin in paediatrics. J Antimicrob Chemother 1983, 11(Suppl B):127.
211. Bergan T Review of the pharmacokinetics and dose dependency of azlocillin in normal subjects and patients with renal insufficiency. J Antimicrob Chemother 1983, 11(Suppl B):101.
212. Placzek M, Whitelaw A, Want S, et al. Piperacillin in early neonatal infection. Arch Dis Child 1983, 58:1006.
213. Thirumoorthi MC, Asmar BI, Buckley JA, et al. Pharmacokinetics of intravenously administered piperacillin in preadolescent children. J Pediatr 1983, 102:941.
214. Kacet N, Roussel-DelVallez M, Gremillet C, et al. Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age. Pediatr Infect Dis J 1992, 11:365.
215. Wilson CB, Koup JR, Opheim KE, et al. Piperacillin pharmacokinetics in pediatric patients. Antimicrob Agents Chemother 1982, 22:442.
216. Reed MD, Goldfarb J, Yamashita TS, Blumer JL Piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994, 38:2817.
217. Johnson GJ Antibiotic-induced hemostatic abnormalities. The Antimicrobial Agents Annual 1 1986, 408. Elsevier, Amsterdam. P.K. Peterson, J. Verhoef (Eds.).
218. Bertino JS, Speck WT The cephalosporin antibiotics. Pediatr Clin North Am 1983, 30:17.
219. Eichenwald HF Antimicrobial therapy in infants and children: update 1976-1985: I. J Pediatr 1985, 107:161.
220. Nelson JD Cefuroxime: a cephalosporin with unique applicability to pediatric practice. Pediatr Infect Dis J 1983, 2:394.
221. Garau J The clinical potential of fourth-generation cephalosporins. Diagn Microbiol Infect Dis 1998, 31:479.
222. Milatovic D, Braveny I Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987, 6:234.
223. Sanders CC, Sanders WE The cephalosporins and cephamycins. The Antimicrobial Agents Annual 2 1987, 70. Elsevier, Amsterdam. P.K. Peterson, J. Verhoef (Eds.).
224. Sheng KT, Huang NN, Promadhattaveddi V Serum concentrations of cephalothin in infants and children and placental transmission of the antibiotic. Antimicrobial Agents Chemother 1964, 10:200.
225. Sakata Y The pharmacokinetic studies of cephalothin, cefazolin and cefmetazole in the neonates and the premature babies. Kurume Med J 1980, 27:275.
226. Hallberg T, Svenningsen NW Cephalothin in neonatal infections. Acta Paediatr Scand 1970, 206(Suppl):110.
227. Plaisance KI, Nightingale CH, Quintiliani R Pharmacology of the cephalosporins. Beta-Lactam Antibiotics for Clinical Use 1986, 285. Marcel Dekker, New York. S.F. Queener, J.A. Webber, S.W. Queener (Eds.).
228. Chang N, Ito T, Saito H, et al. Studies on cefazolin in obstetrics and gynecology with special reference to its clinical pharmacology in the neonate. Advances in Antimicrobial and Antineoplastic Chemotherapy: Progress in Research and Clinical Application, vol 1 1972, 1187. University Parka Press, Baltimore. M. Hejzlar, M. Semonsky, S. Masak (Eds.).
229. Boothman R, Kerr MM, Marshall MJ, et al. Absorption and excretion of cephalexin by the newborn infant. Arch Dis Child 1973, 48:147.
230. Chin KC, Kerr MM, Cockburn F, et al. A pharmacological study of cefaclor in the newborn infant. Curr Med Res Opin 1981, 7:168.
231. McCracken GH, Ginsburg CM, Clahsen JC, et al. Pharmacokinetics of cefaclor in infants and children. J Antimicrob Chemother 1978, 4:515.
232. Renlund M, Pettay O Pharmacokinetics and clinical efficacy of cefuroxime in the newborn period. Proc R Soc Med 1977, 70(Suppl 9):183.
233. Dash CH, Kennedy MRK, Ng SH Cefuroxime in the first week of life. Current Chemotherapy and Infectious Disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy 1980, 1161. American Society for Microbiology, Washington, DC. J.D. Nelson, C. Grassi (Eds.).
234. de Louvois J, Mulhall A, Hurley R Cefuroxime in the treatment of neonates. Arch Dis Child 1982, 57:59.
235. Wilkinson PJ, Belohradsky BH, Marget WA Clinical study of cefuroxime in neonates. Proc R Soc Med 1977, 70(Suppl 9):183.
236. von Hattingberg HM, Marget W, Belohradsky BH, et al. Pharmacokinetics of cefotaxime in neonates and children: clinical aspects. J Antimicrob Chemother 1980, 6(Suppl A):113.
237. Kafetzis DA, Brater DC, Kapiki AN, et al. Treatment of severe neonatal infections with cefotaxime: efficacy and pharmacokinetics. J Pediatr 1982, 100:483.
238. McCracken GH, Threlkeld NE, Thomas ML Pharmacokinetics of cefotaxime in newborn infants. Antimicrob Agents Chemother 1982, 21:683.
239. de Louvois J, Mulhall A, Hurley R The safety and pharmacokinetics of cefotaxime in the treatment of neonates. Pediatr Pharmacol 1982, 2:275.
240. Crooks J, White LO, Burville LJ, et al. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates. J Antimicrob Chemother 1984, 14(Suppl B):97.
241. Bëguë P, Safran C, Quiniou F, et al. Comparative pharmacokinetics of four new cephalosporins: moxalactam, cefotaxime, cefoperazone and ceftazidime in neonates. Dev Pharmacol Ther 1984, 7(Suppl 1):105.
242. Chamberlain J, Coombes JD, Dell D, et al. Metabolism of cefotaxime in animals and man. J Antimicrob Chemother 1980, 6(Suppl A):69.
243. Jones RN, Barry AL, Thornsberry C Antimicrobial activity of desacetyl-cefotaxime alone and in combination with cefotaxime: evidence of synergy. Rev Infect Dis 1982, 4:S366.
244. von Loewenich V, Miething R, Uihlein M, et al. Levels of cefotaxime and desacetyl-cefotaxime in the cerebrospinal fluid of newborn and premature infants. Padiatr Padol 1983, 18:361.
245. Wells TG, Trang JM, Brown AL, et al. Cefotaxime therapy of bacterial meningitis in children. J Antimicrob Chemother 1984, 14(Suppl B):181.
246. Cherubin CE, Corrado ML, Nair SR, et al. Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics. Rev Infect Dis 1982, 4:S453.
247. McCracken GH, Siegel JD, Threlkeld N, et al. Ceftriaxone pharmacokinetics in newborn infants. Antimicrob Chemother 1983, 23:341.
248. James J, Mulhall A, de Louvois J Ceftriaxone-clinical experience in the treatment of neonates. J Infect 1985, 11:25.
249. Mulhall A, de Louvois J, James J Pharmacokinetics and safety of ceftriaxone in the neonate. Eur J Pediatr 1985, 144:379.
250. Martin E, Koup JR, Paravicini U, et al. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J Pediatr 1984, 105:475.
251. Guggenbichler JP, Parth J, Frisch H Pharmacokinetic investigation of ceftriaxone in premature and newborn babies. Padiatr Padol 1986, 21:31.
252. del Rio M, McCracken GH, Nelson JD, et al. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother 1982, 22:622.
253. Latif R, Dajani AS Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis. Antimicrob Agents Chemother 1983, 23:46.
254. Rosenfeld WN, Evans HE, Batheja R, et al. Pharmacokinetics of cefoperazone in full-term and premature neonates. Antimicrob Agents Chemother 1983, 23:866.
255. Philips JB, Braune K, Ravis W, et al. Pharmacokinetics of cefoperazone in newborn infants. Pediatr Pharmacol 1984, 4:193.
256. Bosso JA, Chan GM, Matsen JM Cefoperazone pharmacokinetics in preterm infants. Antimicrob Agents Chemother 1983, 23:413.
257. Assael BM, Boccazzi A, Caccamo ML, et al. Clinical pharmacology of ceftazidime in paediatrics. J Antimicrob Chemother 1983, 12(Suppl A):341.
258. Prinsloo JG, Delport SD, Moncrieff J, et al. A preliminary pharmacokinetic study of ceftazidime in premature, newborn and small infants. J Antimicrob Chemother 1983, 12(Suppl A):361.
259. Gooch WM, Swenson E Neonatal pharmacokinetic characteristics of ceftazidime. Program and Abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy 1983, 237. American Society for Microbiology, Washington, DC, (abstract).
260. McCracken GH, Threlkeld N, Thomas ML Pharmacokinetics of ceftazidime in newborn infants. Antimicrob Agents Chemother 1984, 26:583.
261. Prinsloo JG, Delport SD, Moncriegg J, et al. Pharmacokinetics of ceftazidime in premature, newborn and young infants. S Afr Med J 1984, 65:809.
262. Mulhall A, de Louvois J The pharmacokinetics and safety of ceftazidime in the neonate. J Antimicrob Chemother 1985, 15:97.
263. Low DC, Bissenden JG, Wise R Ceftazidime in neonatal infections. Arch Dis Child 1985, 60:360.
264. Padovani EM, Fanos V, Dal Moro A, et al. Ceftazidime pharmacokinetics in preterm newborns on the first day of life. Biol Res Pregnancy Perinatol 1986, 7:71.
265. Bégué P, Michel B, Chasalette JP, et al. Clinical efficacy and pharmacokinetics of ceftazidime in children and neonates. Pathol Biol 1986, 34:525.
266. de Louvois J, Mulhall A Ceftazidime in the treatment of neonates. Neonatal Therapy: An Update 1986, 249. Elsevier, Amsterdam. F.F. Rubaltelli, B. Granati (Eds.).
267. Blumer J, Reed M, Aronoff S, et al. CSF penetration and pharmacokinetics of ceftazidime in children with bacterial meningitis. Program and Abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy 1983, 237. American Society for Microbiology, Washington, DC, (abstract).
268. Fong IW, Tomkins KB Ceftazidime cerebrospinal fluid penetration in inflamed and non-inflamed meninges. Program and Abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy 1983, 237. American Society for Microbiology, Washington, DC, (abstract).
269. Blumer JL, Reed MD, Knupp C Review of the pharmacokinetics of cefepime in children. Pediatr Infect Dis J 2001, 20:337.
270. Schaad UB The cephalosporin compounds in severe neonatal infection. Eur J Pediatr 1984, 141:143.
271. Roos R New β-lactams. Neonatal Therapy: An Update 1986, 217. Elsevier, Amsterdam. F.F. Rubaltelli, B. Granati (Eds.).
272. Bryan CS, John JF, Pai MS, et al. Gentamicin vs cefotaxime for therapy of neonatal sepsis: relationship to drug resistance. Am J Dis Child 1985, 139:1086.
273. Bang NU, Kammer RB Hematologic complications associated with β-lactam antibiotics. Rev Infect Dis 1983, 5:S380.
274. McCracken GH Use of third-generation cephalosporins for treatment of neonatal infections. Am J Dis Child 1985, 139:1079.
275. Hall MA, Beech RC, Seal DV The use of cefotaxime for treating suspected neonatal sepsis: 2 years experience. J Hosp Infect 1986, 8:57.
276. Parshina NV Clinical efficacy and certain pharmacokinetics characteristics of cefotaxime in premature infants with pneumonia. Antibiot Med Biotekhnol 1986, 31:298.
277. Hoogkamp-Korstanje JAA Activity of cefotaxime and ceftriaxone alone and in combination with penicillin, ampicillin and piperacillin against neonatal meningitis pathogens. J Antimicrob Chemother 1985, 16:327.
278. Macías-Parra M, Gonzalez-Saldaña N, Saltigeral P, et al. Utilidad de la ceftriaxona en el tratamiento de la sepsis neonatal. Rev Enf Infect Pediatr 1992, 6:20.
279. Snelling S, Hart CA, Cooke RWI Ceftazidime or gentamicin plus benzylpenicillin in neonates less than forty-eight hours old. J Antimicrob Chemother 1983, 12(Suppl A):353.
280. Odio CM, Umana MA, Saenz A, et al. Comparative efficacy of ceftazidime vs. carbenicillin and amikacin for treatment of neonatal septicemia. Pediatr Infect Dis J 1987, 6:371.
281. Sáez-Llorens X, O'Ryan M Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 2001, 20:356.
282. Williams JD Aztreonam. The Antimicrobial Agents Annual 2 1987, 47. Elsevier, Amsterdam. P.K. Peterson, J. Verhoef (Eds.).
283. Swabb EA, Cimarusti CM, Henry SA, et al. Aztreonam (SQ 26,776) and other monobactams. Beta-Lactam Antibiotics for Clinical Use 1986, 593. Marcel Dekker, New York. S.F. Queener, J.A. Webber, S.W. Queener (Eds.).
284. Stutman HR, Marks MI, Swabb EA Single-dose pharmacokinetics of aztreonam in pediatric patients. Antimicrob Agents Chemother 1984, 26:196.
285. Likitnukul S, McCracken GH, Threlkeld N, et al. Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants. Antimicrob Agents Chemother 1987, 31:81.
286. Greenman R, Arcey S, Dickinson G, et al. Penetration of aztreonam (SQ 26,776) into human cerebrospinal fluid in the presence of meningeal inflammation. Program and Abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy 1983, 158. American Society for Microbiology, Washington, DC, (abstract).
287. Umana MA, Odio CM, Castro E, et al. Comparative evaluation of aztreonam/ampicillin versus amikacin/ampicillin in neonates with bacterial infections. Pediatr Infect Dis J 1990, 9:175.
288. Uauy R, Mize C, Argyle C, et al. Metabolic tolerance to arginine: implications for the safe use of arginine salt-aztreonam combination in the neonatal period. J Pediatr 1991, 118:965.
289. Bradley JS Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics. Pediatr Infect Dis J 1997, 16:263.
290. Blumer JL Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr Infect Dis J 1996, 15:733.
291. Clissold SP, Todd PA, Campoli-Richards DM Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987, 33:183.
292. Santos-Ferreira MO, Vital JO In-vitro antibacterial activity of imipenem compared with four other β-lactam antibiotics (ceftazidime, cefotaxime, piperacillin and azlocillin) against 828 separate clinical isolates from a Portuguese hospital. J Antimicrob Chemother 1986, 18(Suppl E):23.
293. Williams RJ, Yang YJ, Livermore DM Mechanisms by which imipenem may overcome resistance in gram-negative bacilli. J Antimicrob Chemother 1986, 18(Suppl E):9.
294. Freij BJ, McCracken GH, Olsen KD, et al. Pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother 1985, 27:431.
295. Gruber WC, Rench MA, Garcia-Prats JA, et al. Single-dose pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother 1985, 27:511.
296. Jacobs RF, Kearns GL, Trang JM, et al. Single-dose pharmacokinetics of imipenem in children. J Pediatr 1984, 105:996.
297. Rogers JD, Meisinger MA, Ferber F, et al. Pharmacokinetics of imipenem and cilastatin in volunteers. Rev Infect Dis 1985, 7:S435.
298. Patamasucon P, McCracken GH Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother 1982, 21:390.
299. Modai J, Vittecoq D, Decazes JM, et al. Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis. J Antimicrob Chemother 1985, 16:751.
300. Martinkova J, de Groot R, Chladek J, et al. Meropenem pharmacokinetics in pre-term and full-term neonates. Programs and Abstracts of the 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, March 26-30, 1995 (abstract 686).
301. van Enk JG, Touw DJ, Lafeber HN Pharmacokinetics of meropenem in preterm neonates. Ther Drug Monit 2001, 23:198.
302. Calandra GB, Brown KR, Grad LC, et al. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastin. Am J Med 1985, 78(Suppl 6A):73.
303. Borderon JC, Rastegar A, Laugier J, et al. The effect of imipenem/cilastin on the aerobic faecal flora of children. J Antimicrob Chemother 1986, 18(Suppl E):121.
304. Wong VK, Wright HT, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991, 10:122.
305. Snavely SR, Hodges GR The neurotoxicity of antibacterial agents. Ann Intern Med 1984, 101:92.
306. Hori S, Kurioka S, Matsuda M, et al. Inhibitory effect of cephalosporins on gamma-aminobutyric acid receptor binding in rat synapsis membranes. Antimicrob Agents Chemother 1985, 27:650.
307. Eng RH, Munsif AR, Yangco BG, et al. Seizure propensity with imipenem. Arch Intern Med 1989, 149:1881.
308. Day IP, Goudie J, Nishiki K, Williams PD Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995, 76:239.
309. Collins MA, Tolpin M Clinical evaluation of imipenem-cilastin as a single agent therapy for sepsis neonatorum. Program and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy 1987, 188. and the Collaborative Imipenem-Cilastin Study Group, American Society for Microbiology, Washington, DC, (abstract).
310. Watanakunakorn C Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother 1984, 14(Suppl 3):7.
311. Gross JR, Kaplan SL, Kramer WG, et al. Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol 1985, 5:17.
312. Naqvi SH, Keenam WJ, Reichley RM, et al. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986, 140:107.
313. James A, Koren G, Milliken J, et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987, 31:52.
314. Koren G, James A Vancomycin dosing in preterm infants: prospective verification of new recommendations. J Pediatr 1987, 110:797.
315. Amaker PD, DiPiro JT, Bhatia J Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996, 40:1139.
316. Reiter PD, Doron MW Vancomycin cerebrospinal fluid concentrations after intravenous administration in premature infants. J Perinatol 1996, 16:331.
317. McHenry MC, Gavan TL Vancomycin. Pediatr Clin North Am 1983, 30:31.
318. Spera RV, Farber BF Multiply-resistant Enterococcus faecium. JAMA 1992, 268:2563.
319. McCracken GH Changing pattern of the antimicrobial susceptibilities of Escherichia coli in neonatal infections. J Pediatr 1971, 78:942.
320. Prins JM, Speelman P Once-daily aminoglycosides. Practical guidelines. Neth J Med 1998, 52:1.
321. Mattie H, Craig WA, Pechere JC Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989, 24:281.
322. Skopnik H, Heimann G Once daily aminoglycoside dosing in full term neonates. Pediatr Infect Dis J 1995, 14:71.
323. Hayani KC, Hatzopoulos FK, Frank AL, et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatr 1997, 131:76.
324. Langhendries JP, Battisti O, Bertrand JM, et al. Adaptation in neonatology of the once-daily concept of aminoglycoside administration. Evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 1998, 74:351.
325. Lundergan FS, Glasscock GF, Kim EH, Cohen RS Once-daily gentamicin dosing in newborn infants. Pediatrics 1999, 103:1228.
326. Kotze A, Bartel PR, Sommers DK Once versus twice daily amikacin in neonates: prospective study on toxicity. J Paediatr Child Health 1999, 35:283.
327. Vervelde ML, Rademaker CM, Krediet TG, et al. Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. Ther Drug Monit 1999, 21:514.
328. Agarwal G, Rastogi A, Pyati S, et al. Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants >2500 g. J Perinatol 2002, 22:268.
329. Rastogi A, Agarwal G, Pyati S, Pildes RS Comparison of two gentamicin dosing schedules in very low birth weight infants. Pediatr Infect Dis J 2002, 21:234.
330. Miron D Once daily dosing of gentamicin in infants and children. Pediatr Infect Dis J 2001, 20:1169.
331. de Alba-Romero C, Gómez-Castillo E, Manzanares-Secades C, et al. Once daily gentamicin dosing in neonates. Pediatr Infect Dis J 1998, 17:1169.
332. Avent ML, Kinney JS, Istre GR, Whitfield JM Gentamicin and tobramycin in neonates: comparison of a new extended dosing interval regimen with a traditional multiple daily dosing regimen. Am J Perinatol 2002, 19:413.
333. Solomon R, Kuruvilla KA, Job V, et al. Randomized controlled trial of once vs. twice daily gentamicin therapy in newborn. Indian Pediatr 1999, 36:133.
334. DiCenzo R, Forrest A, Slish JC, et al. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy 2003, 23:585.
335. Fischel-Ghodsian N Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci 1999, 884:99.
336. Skopnik H, Walraf F, Nies B, et al. Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child 1992, 67:57.
337. Hayani KC, Hatzopoulos FK, Fank AL, et al. Pharmacokientics of once-daily dosing of gentamicin in neonates. J Pediatr 1997, 131:76.
338. Skopnik H, Heiman G Once daily aminoglycoside in full term neonates. Pediatr Infect Dis J 1995, 14:71.
339. Miron D, Steinfels M, Reich D. Safety of short course of once-daily dosing of gentamicin in preterm infants. Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, March 1999 (abstract 016).
340. Ristuccia AM, Cunha BA The aminoglycosides. Med Clin North Am 1982, 66:303.
341. Davies JE Resistance to aminoglycosides: mechanisms and frequency. Rev Infect Dis 1983, 5:S261.
342. Kluge RM, Standiford HC, Tatem B, et al. Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1974, 6:442.
343. McCracken GH, Threlkeld N, Thomas ML Intravenous administration of kanamycin and gentamicin in newborn infants. Pediatrics 1977, 60:463.
344. Paisley JW, Smith AL, Smith DH Gentamicin in newborn infants: comparison of intramuscular and intravenous administration. Am J Dis Child 1973, 126:473.
345. Black J, Calesnick B, Williams D, et al. Pharmacology of gentamicin, a new broad-spectrum antibiotic. Antimicrobial Agents Chemother 1963, 161:138.
346. King JT Severe deafness in an infant following oral administration of neomycin. J Med Assoc Ga 1962, 51:530.
347. Nation RL, Huang SM, Vidyasagar D, et al. Absorption of oral neomycin in premature infants with suspected necrotizing enterocolitis. Dev Pharmacol Ther 1982, 5:53.
348. Nunnery AW, Riley HD Gentamicin: pharmacologic observations in newborns and infants. J Infect Dis 1969, 119:402.
349. Hansen TN, Ritter DA, Speer ME, et al. A randomized, controlled study of oral gentamicin in the treatment of neonatal necrotizing enterocolitis. J Pediatr 1980, 97:836.
350. Grylack L, Boehnert J, Scanlon J Serum concentrations of gentamicin following oral administration to preterm newborns. Dev Pharmacol Ther 1982, 5:47.
351. Miranda JC, Schimmel MS, Mimms GM, et al. Gentamicin absorption during prophylactic use for necrotizing enterocolitis. Dev Pharmacol Ther 1984, 7:303.
352. Coyer WF, Wesbey GE, Cech KL, et al. Intravenous gentamicin pharmacokinetics in the small preterm infant. Pediatr Res 1978, 12:403. (abstract).
353. Szefler SJ, Wynn RJ, Clarke DF, et al. Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr 1980, 97:312.
354. Rameis H, Popow C, Graninger W Gentamicin monitoring in low-birth-weight newborns. Biol Res Pregnancy Perinatol 1983, 4:123.
355. Arbeter AM, Saccar CL, Eisner S, et al. Tobramycin sulfate elimination in premature infants. J Pediatr 1983, 103:131.
356. Nahata MV, Powell DA, Durrell DE, et al. Effect of gestational age and birth weight on tobramycin kinetics in newborn infants. J Antimicrob Chemother 1984, 14:59.
357. Cordero L, Arwood L, Hann C, et al. Serum tobramycin levels in low and very low-birth-weight infants. Am J Perinatol 1984, 1:242.
358. Cookson B, Tripps J, Leung T, et al. Evaluation of amikacin dosage regimens in the low and very low-birth-weight newborn. Infection 1980, 8:S239.
359. Nelson JD Duration of neomycin therapy for enteropathogenic Escherichia coli diarrheal disease: a comparative study of 113 cases. Pediatrics 1971, 48:248.
360. McCracken GH, West NR, Horton LJ Urinary excretion of gentamicin in the neonatal period. J Infect Dis 1971, 123:257.
361. McCracken GH, Chrane DF, Thomas ML Pharmacologic evaluation of gentamicin in newborn infants. J Infect Dis 1971, 124:S214.
362. Klein JO, Herschel M, Therakan RM, et al. Gentamicin in serious neonatal infections: absorption, excretion, and clinical results in 25 cases. J Infect Dis 1971, 124:S224.
363. Milner RDG, Ross J, Froud DJR, et al. Clinical pharmacology of gentamicin in the newborn infant. Arch Dis Child 1972, 47:927.
364. Zoumboulakis D, Anagnostakis D, Arseni A, et al. Gentamicin in the treatment of purulent meningitis in neonates and infants. Acta Paediatr Scand 1973, 62:55.
365. Chang MJ, Escobedo M, Anderson DC, et al. Kanamycin and gentamicin treatment of neonatal sepsis and meningitis. Pediatrics 1975, 56:695.
366. Friedman CA, Parks BR, Rawson JE Gentamicin disposition in asphyxiated newborns: relationship to mean arterial blood pressure and urine output. Pediatr Pharmacol 1982, 2:189.
367. Hindmarsh KW, Nation RL, Williams GL, et al. Pharmacokinetics of gentamicin in very low birth weight preterm infants. Eur J Clin Pharmacol 1983, 24:649.
368. Edgren B, Karna P, Sciamanna D, et al. Gentamicin dosing in the newborn: use of a one-compartment open pharmacokinetic model to individualize dosing. Dev Pharmacol Ther 1984, 7:263.
369. Landers S, Berry PL, Kearns GL, et al. Gentamicin disposition and effect on development of renal function in very low birth weight infants. Dev Pharmacol Ther 1984, 7:285.
370. Kildoo C, Modanlou HD, Komatsu G, et al. Developmental pattern of gentamicin kinetics in very low birth weight (VLBW) sick infants. Dev Pharmacol Ther 1984, 7:345.
371. Husson C, Chevalier JY, Jezequel M, et al. Pharmacokinetics study of gentamicin in preterm and term neonates. Dev Pharmacol Ther 1984, 7(Suppl 1):125.
372. Miranda JC, Schimmel MM, James LS, et al. Gentamicin kinetics in the neonate. Pediatr Pharmacol 1985, 5:57.
373. Kasik JW, Jenkins S, Leuschen MP, et al. Postconceptional age and gentamicin elimination half-life. J Pediatr 1985, 106:502.
374. Kliegman RM, Bertino JS, Fanaroff AA, et al. Pharmacokinetics of gentamicin during exchange transfusions in neonates. J Pediatr 1980, 96:927.
375. Bertino JS, Kliegman RM, Myers CM, et al. Alterations in gentamicin pharmacokinetics during neonatal exchange transfusions. Dev Pharmacol Ther 1982, 4:205.
376. Cohen P, Collart L, Prober CG, et al. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J 1990, 9:562.
377. Watterberg KL, Kelly HW, Johnson JD, et al. Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birth weight (<1,500g) babies. Dev Pharmacol Ther 1987, 10:107.
378. Zarowitz BJM, Wynn RJ, Buckwald S, et al. High gentamicin trough concentrations in neonates of less than 28 weeks gestational age. Dev Pharmacol Ther 1982, 5:68.
379. Mulhall A, de Louvois J, Hurley R Incidence of potentially toxic concentrations of gentamicin in the neonate. Arch Dis Child 1983, 58:897.
380. Koren G, Leeder S, Harding E, et al. Optimization of gentamicin therapy in very low birth weight infants. Pediatr Pharmacol 1985, 5:79.
381. Charlton CK, Needelman H, Thomas RW, et al. Gentamicin dosage recommendations for neonates based on half-life predictions from birthweight. Am J Perinatol 1986, 3:28.
382. Mustafa MM, Mertsola J, Ramilo O, et al. Increased endotoxin and interleukin-1 beta concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis associated with intraventricular gentamicin therapy. J Infect Dis 1989, 160:891.
383. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980, 302:1106.
384. Riff L, Schauf V Use of aminoglycosides in the neonate. Semin Perinatol 1982, 6:155.
385. Kaplan JM, McCracken GH, Thomas ML, et al. Clinical pharmacology of tobramycin in newborns. Am J Dis Child 1973, 125:656.
386. Williams G, Stroebel AB, Richardson H, et al. Pharmacokinetics of tobramycin in low-birth-weight newborn infants. Current Chemotherapy and Infectious Disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy 1980, 1163. American Society for Microbiology, DC, Washington. J.D. Nelson, C. Grassi (Eds.).
387. Nahata MC, Powell DA, Gregoire RP, et al. Tobramycin kinetics in newborn infants. J Pediatr 1983, 103:136.
388. Nahata MC, Powell DA, Durrell DE, et al. Tobramycin pharmacokinetics in very low birth weight infants. Br J Clin Pharmacol 1986, 21:325.
389. Howard JB, McCracken GH, Trujillo H, et al. Amikacin in newborn infants: comparative pharmacology with kanamycin and clinical efficacy in 45 neonates with bacterial diseases. Antimicrob Agents Chemother 1976, 10:205.
390. Prober CG, Yeager AS, Arvin AM The effect of chronologic age on the serum concentrations of amikacin in sick term and premature infants. J Pediatr 1981, 98:636.
391. Trujillo H, Manotas R, Londono R, et al. Clinical and laboratory studies with amikacin in newborns, infants and children. J Infect Dis 1976, 134:S406.
392. Yow MD An overview of pediatric experience with amikacin. Am J Med 1977, 62:954.
393. Philips JB, Cassady G Amikacin: pharmacology, indications and cautions for use and dose recommendations. Semin Perinatol 1982, 6:166.
394. Henriksson P, Svenningsen N, Juhlin I, et al. Netilmicin in moderate to severe infections in neonates and infants: a study of efficacy, tolerance and pharmacokinetics. Curr Ther Res 1978, 24:108.
395. Peitersen B, Horlyk H, Nielsen M, et al. Netilmicin: efficacy and tolerance in the treatment of systemic infections in neonates. Scand J Infect Dis (Suppl) 1980, 23:151.
396. Henriksson P, Svenningsen N, Juhlin M, et al. Netilmicin in moderate to severe infections in newborns and infants: a study of efficacy, tolerance and pharmacokinetics. Scand J Infect Dis (Suppl) 1980, 23:155.
397. Chindasilpa V, Schauf V, Hamilton LR, et al. Netilmicin use in pediatric patients. Dev Pharmacol Ther 1980, 1:238.
398. Bergan T, Michalsen H Pharmacokinetic assessment of netilmicin in newborns and older children. Infection 1982, 10:153.
399. Phillips AMR, Milner RDG Clinical pharmacology of netilmicin in the newborn. Arch Dis Child 1983, 58:451.
400. Granati B, Assael BM, Chung M, et al. Clinical pharmacology of netilmicin in preterm and term newborn infants. J Pediatr 1985, 106:664.
401. Kuhn RJ, Nahata MC, Powell DA, et al. Pharmacokinetics of netilmicin in premature infants. Eur J Clin Pharmacol 1986, 29:635.
402. Cordero L, Arwood L, DeCenzo S, et al. Serum netilmicin levels in premature AGA infants. Am J Perinatol 1987, 4:36.
403. Phillips AMR, Milner RDG Tissue concentrations of netilmicin and gentamicin in neonates. J Infect Dis 1984, 149:474.
404. Parini R, Rusconi F, Cavanna G, et al. Evaluation of the renal and auditory function of neonates treated with amikacin. Dev Pharmacol Ther 1982, 5:33.
405. Heimann G Renal toxicity of aminoglycosides in the neonatal period. Pediatr Pharmacol 1983, 3:251.
406. Rajchgot P, Prober CG, Soldin S, et al. Aminoglycoside related nephroxicity in the premature newborn. Clin Pharmacol Ther 1984, 35:394.
407. Aujard Y, Lambert-Zechovsky N, Laudignon N, et al. Gentamicin, nephrotoxic risk and treatment of neonatal infection. Dev Pharmacol Ther 1984, 7(Suppl 1):109.
408. Giacoia GP, Schentag JJ Pharmacokinetics and nephrotoxicity of continuous intravenous infusion of gentamicin in low birth weight infants. J Pediatr 1986, 109:715.
409. Gouyon JB, Aujard Y, Abisror A, et al. Urinary excretion of N-acetyl-glucosaminidase and beta-2-microglobulin as early markers of gentamicin nephrotoxicity in neonates. Dev Pharmacol Ther 1987, 10:145.
410. Tessin I, Trollfors B, Bergmark J, et al. Enzymuria in neonates during treatment with gentamicin or tobramycin. Pediatr Infect Dis J 1987, 6:870.
411. Dahlgren JG, Anderson ET, Hewitt WL Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother 1975, 8:58.
412. Zarfin Y, Koren G, Maresky D, et al. Possible indomethacin-aminoglycoside interaction in preterm infants. J Pediatr 1985, 106:511.
413. Gagliardi L Possible indomethacin-aminoglycoside interaction in preterm infants. J Pediatr 1985, 107:991.
414. Sirinavin S, McCracken GH, Nelson JD Determining gentamicin dosage in infants and children with renal failure. J Pediatr 1980, 96:331.
415. Kalenga M, Devos D, Moulin D, et al. The need for pharmacokinetic monitoring of gentamicin therapy in critically ill neonates. Dev Pharmacol Ther 1980, 7(Suppl 1):130.
416. Herngren L, Broberger U, Wretlind B A simplified model for adjustment of gentamicin dosage in newborn infants. Acta Paediatr Scand 1986, 75:198.
417. de Beukelaer MM, Travis LB, Dodge WF, et al. Deafness and acute tubular necrosis following parenteral administration of neomycin. Am J Dis Child 1971, 121:250.
418. Robinson GC, Cambon KG Hearing loss in infants of tuberculous mothers treated with streptomycin during pregnancy. N Engl J Med 1964, 271:949.
419. Winkel S, Bonding P, Larsen PK, et al. Possible effects of kanamycin and incubation in newborn children with low birth weight. Acta Paediatr Scand 1978, 67:709.
420. Falk SA, Woods NF Hospital noise-levels and potential health hazards. N Engl J Med 1973, 289:774.
421. Johnsonbaugh RE, Drexler HG, Light IJ, et al. Familial occurrence of drug-induced hearing loss. Am J Dis Child 1974, 127:245.
422. Finitzo-Hieber T, McCracken GH, Roeser RJ, et al. Ototoxicity in neonates treated with gentamicin and kanamycin: results of a four-year controlled follow-up study. Pediatrics 1979, 63:443.
423. Johnsonbaugh RE, Drexler HG, Sutherland JM, et al. Audiometric study of streptomycin-treated infants. Am J Dis Child 1966, 112:43.
424. Starr A, Amile RN, Martin WH, et al. Development of auditory function in newborn infants revealed by auditory brainstem potentials. Pediatrics 1977, 60:831.
425. Finitzo-Hieber T, McCracken GH, Brown KC Prospective controlled evaluation of auditory function in neonates given netilmicin or amikacin. J Pediatr 1985, 106:129.
426. Bernard PA, Pecheré JC, Herbert R, et al. Detection of aminoglycoside antibiotic-induced ototoxicity in newborns by brain stem responses audiometry. Current Chemotherapy and Infectious Disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy 1980, 602. American Society for Microbiology, Washington, DC,. J.D. Nelson, C. Grassi (Eds.).
427. Hauch AM, Peitersen B, Peitersen E Vestibular toxicity following netilmicin therapy in the neonatal period. Dan Med Bull 1986, 33:107.
428. Ream CR Respiratory and cardiac arrest after intravenous administration of kanamycin with reversal of toxic effects by neostigmine. Ann Intern Med 1963, 59:384.
429. Pittinger CB, Eryasa Y, Adamson R Antibiotic-induced paralysis. Anesth Analg 1970, 49:487.
430. Warner WA, Sanders E Neuromuscular blockade associated with gentamicin therapy. JAMA 1971, 215:1153.
431. Yamada S, Kuno Y, Iwanaga H Effects of aminoglycoside antibiotics on the neuromuscular junction: I. Int J Clin Pharmacol Ther Toxicol 1986, 24:130.
432. Santos JI, Swensen P, Glasgow LA Potentiation of Clostridium botulinum toxin by aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981, 68:50.
433. McCracken GH New developments in the management of neonatal meningitis. Bacterial Meningitis 1985, 159. Churchill Livingstone, New York. M.A. Sande, A.L. Smith, R.K. Root (Eds.).
434. Bell MJ, Kosloske AM, Benton C, et al. Neonatal necrotizing enterocolitis: prevention of perforation. J Pediatr Surg 1973, 8:601.
435. Egan EA, Mantilla G, Nelson RM, et al. A prospective controlled trial of oral kanamycin in the prevention of neonatal necrotizing enterocolitis. J Pediatr 1976, 89:467.
436. Grylack LJ, Scanlon JW Oral gentamicin therapy in the prevention of neonatal necrotizing enterocolitis: a controlled double-blind trial. Am J Dis Child 1978, 132:1192.
437. Brantley VE, Hiatt IM, Hegyi T The effectiveness of oral gentamicin in reducing the incidence of necrotizing enterocolitis in treated and control infants. Pediatr Res 1980, 14:592. (abstract).
438. Boyle R, Nelson JS, Stonestreet BS, et al. Alterations in stool flora resulting from oral kanamycin prophylaxis of necrotizing enterocolitis. J Pediatr 1978, 93:857.
439. Bell MJ, Shackelford PG, Feigin RD, et al. Alterations in gastrointestinal microflora during antimicrobial therapy for necrotizing enterocolitis. Pediatrics 1979, 63:425.
440. Rowley MP, Dahlenburg GW Gentamicin in prophylaxis of neonatal necrotizing enterocolitis. Lancet 1978, 2:532.
441. Burns JL, Mendelman PM, Levy J, et al. A permeability barrier as a mechanism of chloramphenicol resistance in Haemophilus influenzae. Antimicrob Agents Chemother 1985, 27:46.
442. Gutmann L, Williamson R, Moreau N, et al. Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacter, and Serratia. J Infect Dis 1985, 151:501.
443. Ambrose PJ Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet 1984, 9:222.
444. Friedman CA, Lovejoy FC, Smith AL Chloramphenicol disposition in infants and children. J Pediatr 1979, 95:1071.
445. Glazer JP, Danish MA, Plotkin SA, et al. Disposition of chloramphenicol in low birth weight infants. Pediatrics 1980, 66:573.
446. Kauffman RE, Miceli JN, Strebel L, et al. Pharmacokinetics of chloramphenicol and chloramphenicol succinate in infants and children. J Pediatr 1981, 98:315.
447. Rajchgot P, Prober CG, Soldin S, et al. Initiation of chloramphenicol therapy in the newborn infant. J Pediatr 1982, 101:1018.
448. Nahata MC, Powell DA Comparative bioavailability and pharmacokinetics of chloramphenicol after intravenous chloramphenicol succinate in premature infants and older patients. Dev Pharmacol Ther 1983, 6:23.
449. Rajchgot P, Prober C, Soldin S, et al. Chloramphenicol pharmacokinetics in the newborn. Dev Pharmacol Ther 1983, 6:305.
450. Mulhall A, de Louvois J, Hurley R The pharmacokinetics of chloramphenicol in the neonate and young infant. J Antimicrob Chemother 1983, 12:629.
451. Hodgman JE, Burns LE Safe and effective chloramphenicol dosages for premature infants. Am J Dis Child 1961, 101:140.
452. Ziegra SR, Storm RR Dosage of chloramphenicol in premature infants. J Pediatr 1961, 58:852.
453. Dunkle LM Central nervous system chloramphenicol concentration in premature infants. Antimicrob Agents Chemother 1978, 13:427.
454. Laferriere CI, Marks MI Chloramphenicol properties and clinical use. Pediatr Infect Dis J 1982, 1:257.
455. Mauer SM, Chavers BM, Kjellstrand CM Treatment of an infant with severe chloramphenicol intoxication using charcoal-column hemoperfusion. J Pediatr 1980, 96:136.
456. Kessler DL, Smith AL, Woodrum DE Chloramphenicol toxicity in a neonate treated with exchange transfusion. J Pediatr 1980, 96:140.
457. Werner JC, Whitman V, Schuler HG, et al. Acute myocardial effects of chloramphenicol in newborn pigs: a possible insight into the gray baby syndrome. J Infect Dis 1985, 152:344.
458. Mulhall A, de Louvois J, Hurley R Chloramphenicol toxicity in neonates: its incidence and prevention. BMJ 1983, 287:1424.
459. Iqbal SM, Srivatsav CBP Chloramphenicol ototoxicity: a case-report. J Laryngol Otol 1984, 98:523.
460. Palchick BA, Funk EA, McEntire JE, et al. Anaphylaxis due to chloramphenicol. Am J Med Sci 1984, 288:43.
461. Hughes WT Trimethoprim and sulfonamides. The Antimicrobial Agents Annual 1 1986, 197. Elsevier, Amsterdam. P.K. Peterson, J. Verhoef (Eds.).
462. Pratt WB Fundamentals of Chemotherapy 1973, Oxford University Press, New York.
463. Daeschner CW, Clark JL, Yow EM A comparative evaluation of sulfonamides. J Pediatr 1957, 50:531.
464. Fichter EG, Curtis JA Sulfonamide administration in newborn and premature infants. Pediatrics 1956, 18:50.
465. Vree TB, Hekster YA, Lippens RJ Clinical pharmacokinetics of sulfonamides in children: relationship between maturing kidney function and renal clearance of sulfonamides. Ther Drug Monit 1985, 7:130.
466. Smith LG, Sensakovic J Trimethoprim-sulfamethoxazole. Med Clin North Am 1982, 66:143.
467. Sabel KG, Brandberg A Treatment of meningitis and septicemia in infancy with a trimethoprim-sulfamethoxazole combination. Acta Pediatr Scand 1975, 54:25.
468. Ardati KO, Thirumoorthi MC, Dajani AS Intravenous trimethoprim-sulfamethoxazole in the treatment of serious infections in children. J Pediatr 1979, 95:801.
469. Greene GR, Heitlinger L, Madden JD Citrobacter ventriculitis in a neonate responsive to trimethoprim-sulfamethoxazole. Clin Pediatr 1983, 22:515.
470. Springer C, Eyal F, Michel J Pharmacology of trimethoprim-sulfamethoxazole in newborn infants. J Pediatr 1982, 100:647.
471. Gleckman R, Alvarez S, Joubert DW Drug therapy reviews: trimethoprim-sulfamethoxazole. Am J Hosp Pharm 1979, 36:893.
472. Washington JA, Wilson WR Erythromycin: a microbial and clinical perspective after 30 years of clinical use. Mayo Clin Proc 1985, 60:189.
473. Burns L, Hodgman J Studies of prematures given erythromycin estolate. Am J Dis Child 1963, 106:280.
474. Fujii R, Grossman M, Ticknor W Micromethod for determination of concentration of antibiotics in serum for application in clinical pediatrics. Pediatrics 1961, 28:662.
475. Patamasucon P, Kaojarern S, Kusmiesz H, et al. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age. Antimicrob Agents Chemother 1981, 19:736.
476. Krowchuk D, Seashore JH Complete biliary obstruction due to erythromycin estolate administration in an infant. Pediatrics 1979, 64:956.
477. Kuder HV Propionyl erythromycin: a review of 20,525 case reports for side effect data. Clin Pharmacol Ther 1960, 1:604.
478. Ludden TM Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985, 10:63.
479. Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin-Knoxville, Tennessee, 1999. MMWR Morb Mortal Wkly Rep 1999, 48:1117.
480. LeFrock JL, Molavi A, Prince RA Clindamycin. Med Clin North Am 1982, 66:103.
481. Hermans PE Lincosamides. The Antimicrobial Agents Annual 1 1986, 103. Elsevier, Amsterdam. P.K. Peterson, J. Verhoef (Eds.).
482. Bell MJ, Shackelford P, Smith R, et al. Pharmacokinetics of clindamycin phosphate in the first year of life. J Pediatr 1984, 105:482.
483. Koren G, Zarfin Y, Maresky D, et al. Pharmacokinetics of intravenous clindamycin in newborn infants. Pediatr Pharmacol 1986, 5:287.
484. Kuo CC, Wang SP, Grayston JT Antimicrobial activity of several antibiotics and a sulfonamide against Chlamydia trachomatis organisms in cell culture. Antimicrob Agents Chemother 1977, 12:80.
485. Martínez-Aguilar G, Hammerman WA, Mason EO, Kaplan SL Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003, 22:593.
486. Frank AL, Marcinak JF, Mangat D, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002, 21:530.
487. Donta ST, Myers MG Clostridium difficile toxin in asymptomatic neonates. J Pediatr 1982, 100:431.
488. Feldman WE Bacteroides fragilis ventriculitis and meningitis: report of two cases. Am J Dis Child 1976, 130:880.
489. De Louvois J, Hurley R Antibiotic concentrations in intracranial pus: a study from a collaborative project. Chemotherapy 1975, 4:61.
490. Danneman BR, Israelski DM, Remington JS Treatment of toxoplasmic encephalitis with intravenous clindamycin. Arch Intern Med 1988, 148:2477.
491. Ayliffe GAJ, Duckworth GJ, Brumfitt W, et al. Guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. J Hosp Infect 1986, 7:193.
492. Dacre JE, Emmerson AM, Jenner EA Nasal carriage of gentamicin- and methicillin-resistant Staphylococcus aureus treated with topical pseudomonic acid. Lancet 1983, 2:1036.
493. Lamb YJ Overview of the role of mupirocin. J Hosp Infect 1991, 19:S27.
494. Casewell MW, Hill RLR Pharmacokinetics of mupirocin after its topical application. J Antimicrob Chemother 1987, 19:1.
495. Leyden JJ Mupirocin: a new topical antibiotic. J Am Acad Dermatol 1990, 5:879.
496. Rahman M, Noble WC, Cookson BD Mupirocin-resistant Staphylococcus aureus. Lancet 1987, 2:387.
497. Bruns DE Renal toxicity caused by the topical application of polyethylene glycol to patients with extensive burns. Burns Incl Therm Inj 1982, 9:49.
498. Shama A, Patole SK, Whitehall JS Intravenous rifampicin in neonates with persistent staphylococcal bacteremia. Acta Pediatr 2002, 91:670.
499. Acocella G, Buniva G, Flauto U, et al. Absorption and elimination of the antibiotic rifampin in newborns and children. In Progress in Antimicrobial and Anticancer Chemotherapy. Proceedings of the Sixth International Congress of Chemotherapists, Tokyo, 1969, p 755.
500. Jager-Roman E, Doyle PE, Baird-Lambert J, et al. Pharmacokinetics and tissue distribution of metronidazole in the newborn infant. J Pediatr 1982, 100:651.
501. Di Pentima MC, Mason EO, Kaplan SL In vitro synergy against Flavobacterium meningosepticum: implications for therapeutic options. Clin Infect Dis 1998, 26:1169.
502. Green SD, Ilunga F, Cheesbrough JS, et al. The treatment of neonatal meningitis due to gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid. J Infect 1993, 26:253.
503. Wessalowski R, Thomas L, Kivit J, Voit T Multiple brain abscesses caused by Salmonella enteritidis in a neonate: successful treatment with ciprofloxacin. Pediatr Infect Dis J 1993, 12:683.
504. Nejjari N, Benomar S, Lahbabi MS Nosocomial infections in neonatal and pediatric intensive care. The appeal of ciprofloxacin. Arch Pediatr 2000, 7:1268.
505. Khaneja M, Naprawa J, Kumar A, Piecuch S Successful treatment of late-onset infection due to resistant Klebsiella pneumoniae in an extremely low birth weight infant using ciprofloxacin. J Perinatol 1999, 19:311.
506. Krcmery V, Filka J, Uher J, et al. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diagn Microbiol Infect Dis 1999, 35:75.
507. van den Oever HL, Versteegh FG, Thewessen EA, et al. Ciprofloxacin in preterm neonates: case report and review of the literature. Eur J Pediatr 1998, 157:843.
508. Sutton AM, Turner TL, Cockburn F, McAllister TA Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn. Rev Infect Dis 1986, 5:S518.
509. Tarral E, Jehl F, Tarral A, et al. Pharmacokinetics of teicoplanin in children. J Antimicrob Chemother 1988, 21:47.
510. Fanos V, Kacet N, Mosconi G A review of teicoplanin in the treatment of serious neonatal infections. Eur J Pediatr 1997, 156:423.
511. Lyseng-Williamson KA, Goa KL Linezolid in infants and children with severe gram-positive infections. Paediatr Drugs 2003, 5:419.
512. Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003, 22:S158.
513. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003, 22:677.